Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

IDO peptide vaccine IO102

A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with IDO peptide vaccine IO102 may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation.
Synonym:IDO-derived vaccine IO102
indoleamine 2,3-dioxygenase-derived peptide vaccine
Code name:IO 102
IO-102
IO102
Search NCI's Drug Dictionary